SOCS3 and cancer: Anti-PD-1 or PD-L1 antibodies can efficaciously remedy a variety of cancers (51), and the results of the present study showed that certain patients with low SOCS3 expression achieved better prognoses after ICB (PD-1 or PD-L1) treatment, such as in patients with kidney cancer, melanoma, and bladder cancer.